Table 6 Occurrence of haematological Grade 3–4 adverse events across treatment cycles
Preferred term | Cycles 1–2 | Cycles 3–4 | Cycles 5–6 | Cycles 7+ | ||||
|---|---|---|---|---|---|---|---|---|
AZA (N = 128) | CCR (N = 130) | AZA (n = 89) | CCR (n = 61) | AZA (n = 75) | CCR (n = 25) | AZA (n = 57) | CCR (n = 17) | |
Any Grade 3–4 TEAE, n (%) | 83 (65) | 99 (76) | 47 (53) | 35 (57) | 33 (44) | 8 (32) | 37 (65) | 13 (77) |
Febrile Neutropenia, n (%) | 23 (18) | 34 (26) | 7 (8) | 7 (12) | 4 (5) | 3 (12) | 3 (5) | 2 (12) |
Thrombocytopenia, n (%) | 24 (19) | 26 (20) | 11 (12) | 8 (13) | 8 (11) | 0 | 9 (16) | 0 |
Neutropenia, n (%) | 16 (13) | 20 (15) | 10 (11) | 9 (15) | 3 (4) | 2 (8) | 12 (21) | 5 (29) |
Anaemia, n (%) | 17 (13) | 21 (16) | 3 (3) | 3 (5) | 1 (1) | 0 | 5 (9) | 0 |